Dudediligence.

Nektar Therapeutics

NKTRNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

20.4M

on 2026-06-30, from 12.2M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-15 reverse split; each bar's tip shows the count as filed.

a raise that quarter, at its price

5M10M15M20M1:15 splitMar2024JunSepDecMar2025JunSepDecMar2026$58.00Jun$92.00

Newest

S-3ASR of 2025-11-12. Not read yet. S-3ASR ↗

$150.0M

Guggenheim Securities, agreement of 2026-05-08. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-14 is not read yet.

Cash

11.7 quarters

$684.3M on 2026-06-30 ÷ $58.4M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-04-21Public offering3,532,609$92.00$325.0M424B5 ↗
2026-02-11Public offering incl. 0.29M pre-funded6,896,552$58.00$400.0M424B5 ↗